Martin Cloutier
Montreal, QC, Canada
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 75 publications
Incremental health care resource utilization, costs, and predictors of high costs in generalized myasthenia gravis.
Journal: Journal of managed care & specialty pharmacy
Published: June 24, 2026
A Matching-Adjusted Indirect Comparison (MAIC) of Centanafadine versus Methylphenidate Hydrochloride in Adults with Attention-Deficit/Hyperactivity Disorder (ADHD): Short-Term Safety and Efficacy Outcomes: Comparaison indirecte ajustée par appariement (MAIC) entre centanafadine et le chlorhydrate de méthylphénidate chez les adultes atteints d'un trouble déficitaire de l'attention avec ou sans hyperactivité (TDAH) : Résultats en matière d'innocuité et d'efficacité à court terme.
Journal: Canadian journal of psychiatry. Revue canadienne de psychiatrie
Published: June 02, 2025
Agitation in individuals with Alzheimer's disease: An assessment of behaviors using the cohen-mansfield agitation inventory in community-dwellers and impact on caregiver experience.
Journal: Dementia (London, England)
Published: May 14, 2025
Healthcare Costs Associated with Adverse Events in Pediatric Patients with Attention-Deficit/Hyperactivity Disorder (ADHD): A Claims-Based Study.
Journal: Advances in therapy
Published: May 08, 2025
Quality of Life and Outcomes Associated with Adverse Effects in Pediatric Patients with Attention-Deficit/Hyperactivity Disorder and Their Parents/Caregivers.
Journal: Journal of child and adolescent psychopharmacology
Published: October 07, 2024
Risk of Invasive Escherichia coli (E. coli) Disease After Elective Urologic Procedures Among Older Adults in the United States.
Journal: Infectious diseases and therapy
Published: September 03, 2024
A matching-adjusted indirect comparison of centanafadine versus lisdexamfetamine, methylphenidate and atomoxetine in adults with attention-deficit/hyperactivity disorder: long-term safety and efficacy.
Journal: Journal of comparative effectiveness research
Published: August 12, 2024
Treatment Preferences of Physicians Treating Adult Patients with Attention-Deficit/Hyperactivity Disorder in the United States and Canada: A Discrete Choice Experiment.
Journal: Neurology and therapy
Published: July 11, 2024
The economic impact of suboptimal treatment and treatment switch among patients with Crohn's disease treated with a first-line biologic - A US retrospective claims database study.
Journal: Journal of medical economics
Published: July 05, 2024
Assessment of centanafadine in adults with ADHD: a matching adjusted indirect comparison versus methylphenidate hydrochloride extended release (Concerta).
Journal: Current medical research and opinion
Published: July 03, 2024
Health care resource utilization and costs associated with psychiatric comorbidities in adult patients with attention-deficit/hyperactivity disorder.
Journal: Journal of managed care & specialty pharmacy
Published: June 02, 2024
Assessment of centanafadine in adults with attention-deficit/hyperactivity disorder: A matching-adjusted indirect comparison vs lisdexamfetamine dimesylate, atomoxetine hydrochloride, and viloxazine extended-release.
Journal: Journal of managed care & specialty pharmacy
Published: June 02, 2024
Last Updated: 09/26/2026